Skip to main content

Advertisement

SpringerLink
Log in

Bipolar Depression: An Evidence-Based Approach

  • BIPOLAR DISORDERS (DAVID S. JANOWSKY, SECTION EDITOR)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Bipolar disorder is a complex, multidimensional illness that is often difficult to treat. Unfortunately, bipolar patients are much more likely to experience depression, which is all too often severe and a potentially lethal phase of the illness. In addition, pharmacotherapies with strong evidence for bipolar depression are limited. Most treatments are based on unsupported extrapolation from the treatment of unipolar depression or are derived largely from the clinical practice experience. In this article, we focus on the treatment of bipolar depression, with particular focus on evidence from the existing literature, to help guide readers in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010;13(8):984–8.

    Article  PubMed  Google Scholar 

  2. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–5.

    Article  PubMed  Google Scholar 

  3. Osby Y, Brandt L, Coreia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psych. 2001;58(9):844–50.

    Google Scholar 

  4. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–50.

    Article  PubMed  CAS  Google Scholar 

  5. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 1996;16 Suppl 1:4–14.

    Article  Google Scholar 

  6. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48:558–72.

    Article  PubMed  CAS  Google Scholar 

  7. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–83.

    Article  PubMed  Google Scholar 

  8. Calabrese JR, Rapport DJ, Shelton MD, Kimmel S. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology. 1998;38:185–91.

    Article  PubMed  CAS  Google Scholar 

  9. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry. 2001;62:565–9.

    Article  PubMed  CAS  Google Scholar 

  10. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–22.

    Article  PubMed  CAS  Google Scholar 

  11. Post RM, Leverich GS, Nolen WA, Kupka RW, Altshuler LL, Frye MA, et al. Stanley foundation bipolar network. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003;5(6):396–406.

    Article  PubMed  Google Scholar 

  12. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–74.

    Article  PubMed  CAS  Google Scholar 

  13. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537–47.

    Article  PubMed  Google Scholar 

  14. • Strejilevich SA, Martino DJ, Marengo E, Igoa A, Fassi G, Whitham EA, Ghaemi SN. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011;23(3):186–92. This study was important in that it evaluated the long-term effects of antidepressants on bipolar illness.

  15. Zornberg GL, Pope Jr HG. treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993;13:397–408.

    Article  PubMed  CAS  Google Scholar 

  16. Strakowski SM, McElroy SL, Keck PE. Clinical efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, editors. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press; 2000. p. 143–57.

    Google Scholar 

  17. Goodwin FK, Jamison KR. Maniccbdepressive illness. New York: Oxford University Press; 1990.

    Google Scholar 

  18. Goodwin FK, Murphy DL, Bunney Jr WF. Lithium carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry. 1969;21:486–96.

    PubMed  CAS  Google Scholar 

  19. Goodwin FK, Murphy DL, Dunner DL, Bunney Jr WF. Lithium response in unipolar versus bipolar depression. Am J Psychiatry. 1972;129:44–7.

    PubMed  CAS  Google Scholar 

  20. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906–12.

    Article  PubMed  CAS  Google Scholar 

  21. • Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57–63. This study compared two older agents that are widely used in bipolar disorder and showed the evidence supporting the use of lithium.

  22. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467–73.

    Article  PubMed  CAS  Google Scholar 

  23. Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87–94.

    Article  PubMed  Google Scholar 

  24. Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health. 2010;19(2):127–41.

    Article  PubMed  Google Scholar 

  25. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9.

    Article  PubMed  Google Scholar 

  26. van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223–31. Epub 2008 Dec 30.

    Article  PubMed  Google Scholar 

  27. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 May 3. doi:10.4088/JCP.09m05934.

  28. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13–20.

    Article  PubMed  CAS  Google Scholar 

  29. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–9.

    Article  PubMed  CAS  Google Scholar 

  30. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9(4):413–25.

    Article  PubMed  CAS  Google Scholar 

  31. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. EMBOLDEN I (Trial 001) investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatr. 2010;71(2):150–62.

    Article  CAS  Google Scholar 

  32. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Bipolar Disord. 2007;9(4):413–25.

    Article  Google Scholar 

  33. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical. Clin Ther. 2004;26(1):125–34.

    Article  PubMed  CAS  Google Scholar 

  34. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239–50.

    Article  PubMed  CAS  Google Scholar 

  35. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–86.

    Article  PubMed  CAS  Google Scholar 

  36. Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T, et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol. 2010;24(7):987–94.

    Article  PubMed  CAS  Google Scholar 

  37. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol and risperidone. Am J Psychiatr. 2006;163:210–6.

    Article  PubMed  Google Scholar 

  38. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115:360–5.

    Article  PubMed  CAS  Google Scholar 

  39. Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT. 2003;19(1):10–6.

    Article  PubMed  Google Scholar 

  40. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression (letter). Am J Psychiatr. 1999;156:798.

    PubMed  CAS  Google Scholar 

  41. Zarate Jr CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Biol Psychiatr. 2004;56(1):54–60.

    Article  CAS  Google Scholar 

  42. Frye MA, Grunze H, Suppes T, McElroy SL, Keck Jr PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatr. 2007;164(8):1242–9.

    Article  PubMed  Google Scholar 

  43. Depakote Product Information. Physicians’ desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.

    Google Scholar 

  44. Esaklith Product Information. Physicians’ desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.

    Google Scholar 

  45. Tegretol Product Information. Physicians’ desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.

    Google Scholar 

  46. Lamictal Product Information. Physicians’ desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.

    Google Scholar 

  47. Zyprexa Product Information. Physicians’ desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Pennsylvania Medical Center, 3535 Market Street, 2nd Floor, Philadelphia, PA, 19104, USA

    Claudia F. Baldassano, Alexander Hosey & Jordan Coello

Authors
  1. Claudia F. Baldassano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Hosey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jordan Coello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia F. Baldassano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldassano, C.F., Hosey, A. & Coello, J. Bipolar Depression: An Evidence-Based Approach. Curr Psychiatry Rep 13, 483–487 (2011). https://doi.org/10.1007/s11920-011-0238-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-011-0238-7

Keywords

Search

Navigation